No 02 2018

Annemarie Munk Riis’ background combines leadership roles at Innovation Fund Denmark and The City of Copenhagen with strategic positions at The Danish Ministry of Industry, Business and Financial Affairs.

The company is opening of a new 8,000-square-meter center supporting its immunodiagnostics business in Uppsala.

Vitalis, a four-day event held at Svensk Mässan in Gothenburg on May 4-7, will deliver insight, strategy, and connections – both within and beyond the sessions – that drive the future of healthcare. 

Through the directed issue, the company will receive approximately SEK 51.9 million.

Nasal drug delivery is a dynamic area in pharmaceutical innovation. What was once a route for decongestants and allergy sprays is now being explored for everything from emergency treatments to vaccines – and even shows potential for future central nervous system therapies.

Researchers at the University of Turku have discovered and characterised at the atomic level a mechanism that enables bacterial pathogens – including hospital bacteria Acinetobacter baumannii and Pseudomonas aeruginosa – to assemble antibiotic-resistant three-dimensional (3D) biofilms.

Elicera Therapeutics provides an update on the development of its iTANK-armed CAR T-cell therapy candidate ELC-401 for the treatment of recurrent glioblastoma.